Pembrolizumab versus Ipilimumab in Advanced Melanoma
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...
Publications
View AllFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...
Institution Info
- Type
- healthcare
- Country
- GB
- Publications
- 2
- Citations
- 9,161
External Links
Identifiers
- ROR
- https://ror.org/050batv17